Clinigen soars on potential for large earnings boost
Clinigen (CLIN:AIM) 925PGain to date: 4.3%Original entry point: Buy at 865p, 11 October 2018Shares in pharma firm Clinigen (CLIN:AIM) have shot up after it agreed to buy the US rights to Novartis' cancer drug Proleukin.The deal,...
21 February 2019